EuroPCR 2023: Late-Breaking Science Video Collection
Published: 18 May 2023
-
Views:
1844
-
Likes:
7
-
Views:
1844
-
Likes:
7
-
Up Next
-
29m 21sPart 2 | Session 1 View from the Thoraxcenter: EuroPCR 23 Late-breaking Science Preview -
30m 41sPart 2 | Session 2 View from the Thoraxcenter: What's Hot at EuroPCR 23?
-
1m 5sPart 4 | Session 1 Dr Lim: Patient Care and Finding Your Passion -
1m 51s -
1m 45sPart 4 | Session 3 Dr Sorajja: Why He Chose Cardiovascular Medicine
-
5m 41sPart 1 | Session 1 EBC TWO Five Year Follow-Up: Two-Stent Vs One for Large Bifurcation Lesions Sandeep Arunothayaraj
-
6m 12sPart 1 | Session 2 BASILICA Vs Chimney-Stenting for TAVR-Related Coronary Obstruction Antonio Mangieri
-
3m 15sPart 1 | Session 3 DRAGONFLY-DMR: Safety and Effectiveness of Dragonfly TMVR System for Mitral Regurgitation D Scott Lim
-
3m 30sPart 1 | Session 4 TRILUMINATE Pivotal: TEER for Tricuspid Regurgitation Paul Sorajja
-
6m 7sPart 1 | Session 5 EBC MAIN Three-Year Follow Up David Hildick-Smith
-
4m 59sPart 1 | Session 6 TVT Registry Analysis: TAVR in Patients with Cardiogenic Shock Abhijeet Dhoble
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023.
More from this programme
Part 1
Expert Interviews
Short, concise overviews of the key data revealed at EuroPCR 2023, focussing on the results and impact on future research.
Part 2
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023.
Part 3
Highlights Reviews
Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.
Part 4
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
EuroPCR 23 – In this late-breaking science interview, we are joined by Prof Frederick Zimmermann (Catharina Hospital, NL) to discuss the findings from a 3-year follow-up of the FAME III trial.
The objective of the FAME 3 trial was to demonstrate the noninferiority of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) in patients with three-vessel disease. Eligible patients were randomly assigned to either FFR-guided PCI (757) or CABG (743) in a 1:1 ratio. The results at 3 years demonstrate no significant difference in death, MI and stroke at 3 years.
Interview Questions
- What is the importance of the FAME 3 trial?
- Could you provide a brief overview of the methodology used and the patient population involved in the FAME 3 trial?
- What are the key findings at three years?
- What are some of the limitations of this trial?
- In the context of three-vessel disease, which patients would potentially benefit from FFR-guided PCI?
- What are the next steps and what are the remaining knowledge gaps?
Recorded on-site at EuroPCR 2023, Paris.
Editors: Mirjam Boros, Jordan Rance
Video Specialist: Oliver Miles, Dan Brent
Faculty Biographies
Frederik Zimmermann
Dr Frederik Zimmermann is an interventional cardiologist at Catharina Hospital, Eindhoven, NL.
Comments